DESCRIPTION (Adapted from the Investigator's abstract): Prostaglandins (PGs)
are lipid-derived hormones involved in rapid, localized cellular responses.
Their synthesis is catalyzed by the action of the PG-H synthases,
(cyclooxygenases COX-1 and -2). The non-steroidal anti-inflammatory drugs
(NSAIDs), which are used for treating inflammatory diseases including
arthritis; pain, clotting disorders, and cancer inhibit these enzymes. Despite
the widespread use of NSAIDs, our understanding of PG function during
physiological and pathological processes is incomplete. Using COX-1 and COX-2
deficient mice, and normal fetal thymus treated with NSAIDs and PG analogs in
organ culture the investigator demonstrated a critical role for PGs in T-cell
development. The constitutively expressed COX-1 enzyme was required for
efficient T-cell development at the CD4-8- to CD4+8+ transition. COX-2 was
specifically expressed in a subset of medullary epithelial cells. COX-2 was
required during two steps of T-cell development, early thymocyte proliferation
and differentiation, during maturation to the CD4 helper lineage. The
applicant's goal is to understand the role of PG signaling in T-cell
differentiation and selection. To achieve this, the investigator will first
determine which cells produce and respond to PGs, and which molecules are
involved in PG response and regulation. Whether PGs play a role in gamma-delta
T-cell, NK T-cell, NK cell, and thymic dendritic cell development will be
determined. Finally, whether PGs mediate their action by promoting cellular
survival, proliferation or differentiation, will be determined. These questions
will be addressed using COX-1, COX-2, and prostanoid-receptor deficient mice
and fetal thymic organ culture.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
T lymphocytebiological signal transductioncell differentiationdendritic cellslaboratory mouseleukopoiesisnatural killer cellsorgan cultureprostaglandin endoperoxide synthaseprostaglandinsthymus
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
003255213
UEI
G69LHXJ3ABL5
Project Start Date
30-September-2000
Project End Date
31-August-2005
Budget Start Date
01-September-2001
Budget End Date
31-August-2002
Project Funding Information for 2001
Total Funding
$231,300
Direct Costs
$150,000
Indirect Costs
$81,300
Year
Funding IC
FY Total Cost by IC
2001
National Institute of Allergy and Infectious Diseases
$231,300
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI049807-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI049807-02
Patents
No Patents information available for 5R01AI049807-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI049807-02
Clinical Studies
No Clinical Studies information available for 5R01AI049807-02
News and More
Related News Releases
No news release information available for 5R01AI049807-02
History
No Historical information available for 5R01AI049807-02
Similar Projects
No Similar Projects information available for 5R01AI049807-02